Electrophysiological and anatomical characterization of synaptic remodeling in the mouse whisker thalamus by UETA Yoshifumi & MIYATA Mario
Electrophysiological and anatomical
characterization of synaptic remodeling in the
mouse whisker thalamus










Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
ll
OPEN ACCESSProtocolElectrophysiological and anatomical
characterization of synaptic remodeling in the





















remodelingIn the central nervous system, developmental and pathophysiologic conditions cause a large-
scale reorganization of functional connectivity of neural circuits. Here, by using a mouse model
for peripheral sensory nerve injury, we present a protocol for combined electrophysiological and
anatomical techniques to identify neural basis of synaptic remodeling in the mouse whisker
thalamus. Our protocol provides comprehensive approaches to analyze both structural and
functional components of synaptic remodeling.Ueta & Miyata, STAR Protocols
2, 100743
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In the central nervous system, developmental and pathophysiologic conditions
cause a large-scale reorganization of functional connectivity of neural circuits.
Here, by using a mouse model for peripheral sensory nerve injury, we present
a protocol for combined electrophysiological and anatomical techniques to iden-
tify neural basis of synaptic remodeling in the mouse whisker thalamus. Our
protocol provides comprehensive approaches to analyze both structural and
functional components of synaptic remodeling.
For complete details on the use and execution of this protocol, please refer to
Ueta and Miyata, (2021).
BEFORE YOU BEGIN
Structures and functions of neural circuitry in the central nervous system are dynamically refined dur-
ing development and in disease. Because neural and glial mechanisms both involve in the induction
and maintenance of synaptic remodeling, investigating how neural or glial mechanisms change
physiological and morphological properties of synapses and characterizing interactions between
neurons and glial cells, such as astrocytes or microglia, are of particular importance to understand
neural mechanisms underlying developmental maturation or etiology.
We have recently reported the microglia-dependent mechanism of structural and functional synaptic re-
modeling in themousewhisker thalamus (UetaandMiyata, 2021),which is triggeredbyperipheral sensory
nerve injury (Nagumo et al., 2020; Takeuchi et al., 2012; 2017). In that study, we have established region-
specific depletion or activationofmicroglia using stereotaxic injections ofmicroglial inhibitor or activator.
Here, we describe step-by-step procedures for development of mouse model for peripheral nerve
injury, stereotaxic injection, and electrophysiological and histological assessment of synaptic remod-
eling in the whisker thalamus. These approaches include fundamental techniques for mouse surgery,
whole-cell patch-clamp using acute brain slices, and immunohistochemistry combined with mouse
genetics, and will be useful for studies investigating neural and glial contribution to synaptic remod-
eling in diverse regions under pathophysiological conditions, and also during development.KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Goat polyclonal anti-Iba1 antibody (1:500–1,000 dilution) Abcam Cat#ab5076; PRID: AB_2224402
Rabbit Polyclonal Anti-Iba1 Antibody (1:500–1,000 dilution) FUJIFILM Wako Pure
Chemical Corporation
Cat#019-19741; PRID: AB_839504
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Rabbit polyclonal anti-NeuN antibody
(1:1,000–5,000 dilution)
Merck (Sigma-Aldrich) Cat#ABN78; PRID: AB_10807945
Mouse monoclonal anti-NeuN antibody
(1:1,000–2,000 dilution)
Merck (Sigma-Aldrich) Cat#MAB377; PRID: AB_2298772
Rabbit polyclonal anti-TMEM119 antibody
(1:500–1,000 dilution)
Abcam Cat#ab209064; PRID: AB_2800343
Guinea Pig Polyclonal Anti-VGluT2 Antibody
(1:500–1,000 dilution)




Guinea Pig Polyclonal Anti-VGluT2 Antibody
(1:1,000–5,000 dilution)
Merck (Sigma-Aldrich) Cat#AB2251-I; PRID: AB_2665454
Rabbit Polyclonal Anti-VGluT2 Antibody
(1:500–1,000 dilution)




Donkey anti-Guinea Pig IgG Secondary Antibody,




Donkey Anti-Guinea Pig IgG Secondary Antibody,




Donkey anti-Rabbit IgG Secondary Antibody,
Alexa Fluor 488 conjugate (1:500 dilution)
Thermo Fisher Scientific Cat#A21206; PRID: AB_2535792
Chemicals, peptides, and recombinant proteins
Agar FUJIFILM Wako Pure
Chemical Corporation
Cat#010-15815; CAS: 9002-18-0
Agarose S Nippon Gene Co., Ltd. Cat#312-01193; CAS: 9012-36-6
Atipamezole (Antisedan) Nippon Zenyaku Kogyo Co., Ltd. CAS: 104075-48-1
Bicuculline methochloride Tocris Cat#0131; CAS: 53552-05-9
Biocytin Toronto Research
Chemicals Inc. or Sigma
Cat#B388100 or #B4261, CAS: 576-19-2
Butorphanol (Vetorphale) Meiji Seika Pharma Co., Ltd. CAS: 42408-82-2
CaCl2$2H2O Kanto Chemical Co., Inc. Cat#07058-00; CAS: 10035-04-8
CGP55845 Tocris Cat#1248; CAS: 149184-22-5
Cholera toxin subunit B, Alexa
Fluor 555 conjugate
Thermo Fisher Scientific Cat#C34776
Cholera toxin subunit B, Alexa
Fluor 647 conjugate
Thermo Fisher Scientific Cat#C34778
Chromium (III) potassium sulfate$12H2O Kanto Chemical Co., Inc. Cat#07360-00; CAS: 7788-99-0
Clodronate liposomes Katayama Chemical Cat#160-0430-1
CsMeSO3 Merck (Sigma-Aldrich) Cat#C1426; CAS: 2550-61-0
CsOH 50 wt. % solution in water Merck (Sigma-Aldrich) Cat#232041; CAS: 21351-79-1
D-(+)-glucose FUJIFILM Wako Pure Chemical Corp. Cat#049-31165; CAS: 50-99-7
EDTA$2Na$2H2O Nacalai Tesque Cat#15111-45; CAS: 6381-92-6
EGTA Nacalai Tesque Cat#15214-92; CAS: 67-42-5
Ethylene glycol Merck (Sigma-Aldrich) Cat#09-1540-5; CAS: 107-21-1
Fluoromount-G (refractive index, ~1.4) SouthernBiotech Cat#0100-01
Glycerol Nacalai Tesque Cat#17017-35; CAS: 56-81-5
HCl (1 M) FUJIFILM Wako Pure
Chemical Corporation
Cat#083-01095; CAS: 7647-01-0
Heparin sodium salt from porcine
intestinal mucosa
Merck (Sigma-Aldrich) Cat#H3393; CAS: 9041-08-1
HEPES Merck (Sigma-Aldrich) Cat#H3375; CAS: 7365-45-9
Isoflurane Viatris (Mylan N.V.) CAS: 26675-46-7
KCl FUJIFILM Wako Pure
Chemical Corporation
Cat#163-03545; CAS: 7447-40-7
K-gluconate Merck (Sigma-Aldrich) Cat#G4500; CAS: 299-27-4
KOH (1 M) FUJIFILM Wako Pure
Chemical Corporation
Cat#169-03885; CAS: 1310-58-3
Lactic acid Nacalai Tesque Cat#20006-62; CAS: 50-21-5
Lipopolysaccharides from E.Coli O26 FUJIFILM Wako Pure
Chemical Corporation
Cat#120-05131; CAS: 93572-42-0
(Continued on next page)
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Medetomidine (Domitor) Nippon Zenyaku Kogyo Co., Ltd. CAS: 86347-15-1
MgCl2$6H2O FUJIFILM Wako Pure
Chemical Corporation
Cat#135-00165; CAS: 7791-18-6
Midazolam Sandoz K.K. CAS: 59467-70-8
myo-Inositol FUJIFILM Wako Pure
Chemical Corporation
Cat#094-00281; CAS: 87-89-8
Na2-ATP Merck (Sigma-Aldrich) Cat#A7699; CAS: 34369-07-8
Na2HPO4$12H2O FUJIFILM Wako Pure
Chemical Corporation
Cat#196-02835; CAS: 10039-32-4
NaCl FUJIFILM Wako Pure
Chemical Corporation
Cat#191-01665; CAS: 7647-14-5
Na-GTP Merck (Sigma-Aldrich) Cat#G8877; CAS: 36051-31-7
NaH2PO4$2H2O FUJIFILM Wako Pure
Chemical Corporation
Cat#192-02815; CAS: 13472-35-0
NaHCO3 FUJIFILM Wako Pure
Chemical Corporation
Cat#191-01305; CAS: 144-55-8
NaOH (1 M) FUJIFILM Wako Pure
Chemical Corporation
Cat#192-02175; CAS: 1310-73-2
Neurobiotin Vector Laboratories Cat#SP-1120; CAS: 111822-45-8
NeuroTrace 435/455 Blue Fluorescent
Nissl Stain (1:100–200 dilution)
Thermo Fisher Scientific Cat#N21479
Normal donkey serum ImmunoBioScience Corp. Cat#IHR-8135
Ofloxacin gel (Tarivid opthalamic ointment 0.3%) Santen Pharmaceutical Co., Ltd. CAS: 82419-36-1
Paraformaldehyde TAAB laboratories Equipment Ltd. Cat#P001; CAS: 30525-89-4
Picric acid Nacalai Tesque Cat#27926-02; CAS: 88-89-1
PLX3397 (Pexidartinib) Selleck Chemicals Cat#S7818; CAS: 1029044-16-3
ProLong Gold Antifade Mountant
(refractive index, 1.47)
Thermo Fisher Scientific Cat#P36934
QX314 (lidocaine N-ethyl bromide) Merck (Sigma-Aldrich) Cat#L5783, CAS: 21306-56-9
Sevoflurane Viatris (Mylan N.V.) CAS: 28523-86-6
SlowFade Diamond Antifade Mountant
(refractive index, 1.47)
Thermo Fisher Scientific Cat#S36972
Sodium ascorbate ((+)-sodium L-ascorbate) Merck (Sigma-Aldrich) Cat#A7631; CAS: 134-03-2
Sodium pyruvate (pyruvic acid sodium salt) Nacalai Tesque Cat#29806-12; CAS: 113-24-6
Spongel LTL Pharma N/A
Streptavidin, Alexa Fluor 488 conjugate
(1:500 dilution)
Thermo Fisher Scientific Cat#S11223
Sucrose FUJIFILM Wako Pure
Chemical Corporation
Cat#196-00015; CAS: 57-50-1
Thiourea FUJIFILM Wako Pure
Chemical Corporation
Cat#204-01202; CAS: 62-56-6
Tris base (Trizma base) Merck (Sigma-Aldrich) Cat#T6066; CAS: 77-86-1
Tris-HCl Nacalai Tesque Cat#35433-15; CAS: 1185-53-1
Trisodium citrate dihydrate FUJIFILM Wako Pure
Chemical Corporation
Cat#204-16675; CAS: 6132-04-3
Triton X-100 Nacalai Tesque Cat#12967-32; CAS: 9002-93-1
Xylocaine jelly 2% (lidocaine hydrochloride) Aspen Japan K.K. CAS: 73-78-9
Xylocaine with 1:80,000 adrenaline Dentsply Sirona K.K. CAS: 73-78-9 (for lidocaine hydrochloride),
51-43-4 (for adrenaline)
Experimental models: organisms/strains
Mouse: C57BL/6JJmsSlc Sankyo Labo Service Corporation Inc. MGI: 5488963; PRID: MGI:5488963
Mouse: Egr2tm2(cre)Pch/J (Krox20-Cre) The Jackson Laboratory JAX: 025744; PRID: IMSR_JAX:025744
Mouse: B6;129S-Gt(ROSA)
26Sortm34.1(CAG-Syp/tdTomato)Hze/J (Ai34D)
The Jackson Laboratory JAX: 012570; RRID: IMSR_JAX:012570
Software and algorithms
Adobe Photoshop/Illustrator CC Adobe Inc. https://www.adobe.com/
Igor Pro 6 WaveMetrics https://www.wavemetrics.com/
ImageJ NIH https://imagej.nih.gov/ij/
(Continued on next page)
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NeuroMatic Rothman and Silver, 2018 http://www.neuromatic.thinkrandom.com/
pClamp 8 Molecular Devices https://www.moleculardevices.com/
Zen Carl Zeiss https://www.zeiss.de/corporate/home.html
Other
1 or 20 mL syringe Terumo Corporation Cat#SS-01T or SS-20ESZ
21-, 26-, or 27-gauge syringe needle Terumo Corporation Cat#NN-2138R, NN-2613S, or NN-2719S
35G beveled needle World Precision Instruments Cat#NF35BV-2
Anesthetic apparatus with anesthesia
induction chamber
Shinano MFG Co. Ltd. Cat#SN-487-0T
Aron Alpha (cyanoacrylate) Toagosei Co. Ltd. Cat#31204
Concentric stimulating electrode Inter Medical Co. Ltd. Cat#IMB-160820
Confocal laser scanning microscope Carl Zeiss Cat#LSM710
Cooled CCD camera (for histology) Quantum Scientific Imaging, Inc. Cat#QSI RS 6.1
Coverslip (24 3 32, 40, 50, and 60 mm) Matsunami Glass Ind. Ltd. Cat#C024321, C024401,
C024501, and C024601
DC temperature controller (for surgery) FHC Cat#40-90-8D
Digitizer Molecular Devices Cat#Digidata 1322A
Electrical tape Yamato Co. Ltd. Cat#NO200-19






Carl Zeiss Cat#Axio Scope.A1
Flexible needle World Precision Instruments Cat#MF28G-5
Flow tube for peristaltic pump
(for electrophysiology; I.D., 1.29 mm)
M&S Instruments Inc. F117940
Flow tube for peristaltic pump
(for paraformaldehyde fixation; I.D., 2.28 mm)
M&S Instruments Inc. F117946
Fluorescence microscope Keyence Cat#BZ-X810
Glass capillary (O.D., 1.0 and I.D., 0.6 mm) Narishige Cat#G-1
Glass capillary (O.D., 1.5 and I.D., 0.9 mm) Narishige Cat#G-1.5
Glass capillary (O.D., 1.5 and I.D., 0.86 mm) Sutter Instrument Cat#B150-86-10
Glass capillary (O.D., 1.5 and I.D., 1.17 mm) Harvard Apparatus Cat#30-0062
Glass microscope slides Matsunami Glass Ind. Ltd. Cat#S2441
Hamilton syringe (10 mL) World Precision Instruments Cat#Nanofil
Heat pad Natsume Seisakusho Co. Ltd. Cat#KN-475-2-40
Injector blade (for preparing thin
sections of the fixed brain)
Schick Japan K. K. Cat#SII-10
Iontophoresis pump Kation Scientific Cat#BAB-600
Magnetic hot plate stirrer IKA Cat#RH B2 S004
Microelectrode amplifier Molecular Devices LLC. Cat#Multiclamp 700A
Micromanipulator (for electrophysiology) Sutter Instrument Cat#MP-225
Micromanipulator (for stereotaxic injection) Narishige Cat#SM-15R/SM-15M-2
Micromotor system Minitor Co. Ltd. Cat#Minimo one series ver.2
Micropipette puller Sutter Instrument Cat#P-1000 or P-97
Micro-Sample Osmometer Fiske Associates Inc. Cat#Model 210
Microsyringe pump controller World Precision Instruments Cat#Micro 4
Microtome blade (for trimming the fixed brain) Feather Safety Razor Co. Ltd. Cat#A35
Near-infrared camera Hamamatsu Photonics Cat#C3077-79
Near-infrared camera controller Hamamatsu Photonics Cat#C2741-62
Paraffin oven (laboratory incubator) Hirasawa Works Cat#SC-4d-CP
Peristaltic pump Gilson Inc. Cat#Minipuls 3
pH indicator paper (pH 5.0–10.0) Merck Cat#109533
pH meter Horiba Ltd. Cat#B-712
Razor blade (for preparing acute brain slices) Feather Safety Razor Co. Ltd. Cat#81-S
Rodent brain matrix ASI Instruments Inc. Cat#RBM-2000C
Shaker TAITEC Corporation Cat#Mix-VR and NR-80
Steel bur (Midwest carbide bur) Dentsply Sirona K.K. Cat#386301
(Continued on next page)
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Stereo microscope (for surgery) Leica Microsystems Inc. Cat#M60
Stereotaxic apparatus Narishige Cat#SR-5M-HT
Stimulus isolator A.M.P.I. Cat#Iso-Flex
Surgical blade (for trimming the brain) Feather Safety Razor Co. Ltd Cat#21
Syringe filter (0.2 mm, non-sterile) Millipore (Merck) Cat#SLLGH04NL
Temperature controller (line heater) Warner Instruments Cat#TC-324B
Vibratome Leica Microsystems Inc. Cat#VT-1000S and VT-1200S
Vinyl repair patch Otsuka Corporation Cat#TGK-280
Water bath system AS ONE Corporation Cat#TR1
ll
OPEN ACCESSProtocolMATERIALS AND EQUIPMENT103 artificial cerebrospinal fluid (aCSF) stock solution
Reagent Final concentration Amount
NaCl 1.25 M 73.05 g
NaHCO3 260 mM 21.84 g
NaH2PO4$2H2O 12.5 mM 1.95 g
KCl 25 mM 1.86 g
ddH2O N/A Fill up to 1,000 mL
Total N/A 1,000 mL
The solution can be stored at 4C for 1 month.
aCSF solution
Reagent Final concentration Amount
103 aCSF 13 100 mL
1 M CaCl2 solution 2 mM 2 mL
1 M MgCl2 solution 1 mM 1 mL
D-(+)-Glucose 20 mM 3.6 g
ddH2O N/A Fill up to 1,000 mL
Total N/A 1,000 mL
Add 1 M CaCl2 solution and 1 MMgCl2 solution after diluting 103 aCSF solution with ddH2O and bubbled with a mixture of
95% O2 and 5% CO2 for 10–30 min at 20
C–25C.
Although the solution may be stored at 4C for one week, we recommend to prepare the fresh solution on the day of use.
Osmolarity of the solution is 310 G 5 mOsm.
pH of the solution falls to 7.2–7.3 after bubbling with a mixture of 95% O2 and 5% CO2 for 10 min at 20
C–25C .1 M CaCl2 solution
Reagent Final concentration Amount
CaCl2$2H2O 1 M 14.7 g
ddH2O N/A Fill up to 100 mL
Total N/A 100 mL
The solution can be stored at 4C for at least 3 months.
1 M MgCl2 solution
Reagent Final concentration Amount
MgCl2$6H2O 1 M 20.3 g
ddH2O N/A Fill up to 100 mL
Total N/A 100 mL
The solution can be stored at 4C for at least 3 months.
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Cutting solution (sucrose-based solution)
Reagent Final concentration Amount
Sucrose 234 mM 80.1 g
NaHCO3 25 mM 2.1 g
NaH2PO4$2H2O 1.25 mM 0.2 g
KCl 2.5 mM 0.19 g
1 M CaCl2 solution 0.5 mM 0.5 mL
1 M MgCl2 solution 10 mM 10 mL
myo-Inositol 0.5 mM 0.09 g
D-(+)-Glucose 20 mM 3.6 g
ddH2O N/A Fill up to 1,000 mL
Total N/A 1,000 mL
The composition is originally based on the previous study (Gentet and Ulrich, 2003).
The solution can be stored at 4C for 1 month.
Osmolarity of the solution is 360 G 10 mOsm.


































ProtocolAlternatives: Cold aCSF solution can be used as the cutting solution.53 Cs+-based pipette internal solution for voltage-clamp recording
gent Final concentration Amount
eSO3 120 mM 547 mg
l 20 mM 23 mg
314 5 mM 34 mg
-ATP 2 mM 22 mg
GTP 0.5 mM 5 mg
CaCl2 solution 0.1 mM 2 mL
MgCl2 solution 2 mM 40 mL
ES 10 mM 48 mg
TA 1 mM 8 mg
2O N/A Fill up to 16 mL
al N/A 16 mL
15 mL of ddH2O first and mix.
r pH adjustment to 7.2–7.3 with CsOH, fill up to 16 mL by ddH2O.
.8-mL aliquot in the 1.5 mL or 2 mL microtube can be stored at 30C for at least 3 months.
w an aliquot on the day of use, and adjust osmolarity to 290 mOsm by adding ddH2O.
er the solution (nearly 1 mL of total amount) using non-sterile 0.20 mm mini-syringe filter before use.
cessary, add 0.5% (w/v) biocytin and vortex the solution before adjusting osmolarity. Sonication is effective to prepare the
cytin solution.
cytin can also be dissolved in the initial step before aliquot.
uots can be stored at 30C for at least 3 months as described above.
ce prepared, the solution may be stored at 4C for a week.Alternatives: Neurobiotin can be used instead of biocytin for visualizing cell morphology.53 K+-based pipette internal solution for current-clamp recording
gent Final concentration Amount
luconate 130 mM 609 mg
-ATP 2 mM 22 mg
GTP 0.3 mM 3 mg
MgCl2 solution 2 mM 40 mL
ES 10 mM 48 mg
(Continued on next page)
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Reagent Final concentration Amount
EGTA 0.2 mM 1.6 mg
Biocytin 0.5% (w/v) 100 mg
ddH2O N/A Fill up to 16 mL
Total N/A 16 mL
Prepare the solution similar to the Cs+-based internal solution described above, but adjust pH using KOH.
Biocytin is always included in the K+-based internal solution in our experiments.
A 0.8-mL aliquot in the 1.5 mL or 2 mL microtube can be stored at 30C for at least 3 months.
Thaw a 0.8-mL aliquot on the day of use, and adjust osmolarity to 290 mOsm by adding ddH2O.
Total amount of the solution becomes nearly 1 mL.
Filter the solution before use as described above.
Once prepared, the solution may be stored at 4C for a week.
ll
OPEN ACCESSProtocolCRITICAL: As it is difficult to measure the small amount of reagent, you can prepare largeramount of internal solutions or concentrated solution, especially for Na2-ATP, Na-GTP, and
EGTA. We adjust osmolarity just before the experiment, because osmolarity may be
slightly changed during the storage. For more convenience, you can fill up to 20 mL after
pH adjustment and adjust osmolarity to 290 mOsm. In that case, a 1-mL aliquot can be
stored, but we recommend to measure osmolarity of thawed solution just before the
experiment.0.1 M phosphate buffer (PB) (pH 7.4)
Reagent Final concentration Amount
Na2HPO4$12H2O 80 mM 29 g
NaH2PO4$2H2O 20 mM 2.95 g
ddH2O N/A Fill up to 1,000 mL
Total N/A 1,000 mL
If pH is lower than 7.4, add few drops of 1 M NaOH and adjust pH to 7.4.
Add 9 g NaCl for preparing phosphate buffered saline (PBS). The solution can be stored at 4C for 1 year.0.05 M Tris buffer (TB) (pH 7.6)
Reagent Final concentration Amount
Tris-HCl 500 mM 6.06 g
Tris base 11.5 mM 1.39 g
ddH2O N/A Fill up to 1,000 mL
Total N/A 1,000 mL
Add 0.9 g NaCl for preparing tris buffered saline (TBS). The solution can be stored at 4C for 1 year.
Prefixative solution (sucrose-based solution)
Reagent Final concentration Amount
Sucrose 250 mM 8.5 g
1 M MgCl2 solution 5 mM 0.5 mL
0.1 M PB 20 mM 20 mL
ddH2O N/A Fill up to 100 mL
Total N/A 100 mL
The solution can be stored at 4C for 1 month.



































ProtocolAlternatives: Saline (0.9% NaCl) can be used as the prefixative solution. To prevent blood
coagulation, heparin can be included in the prefixative solution (10–20 units/mL).ative solution (4% paraformaldehyde and 0.2% picric acid)
gent Final concentration Amount
aformaldehyde 4% (w/v) 40 g
ic acid 0.2% (w/v) 2 g
M PB 0.1 M 500 mL
2O N/A Fill up to 1,000 mL
al N/A 1,000 mL
500 mL 0.2 M PB and 300 mL ddH2O in a 1000-mL conical flask.
40 g paraformaldehyde powder.
t the solution at 60C and stir the solution until paraformaldehyde powder is completely solubilized when the cloudy so-
on becomes clear. It will require 1–2 h. Add 7–9 drops of 1 M NaOH using a 3-mL disposable transfer pipette if necessary.
of the solution is adjusted to around 7.5 using a pH indicator paper.
l the solution to 4C by placing the flask on ice.
2 g picric acid powder and stir until the powder is completely solubilized. It will finish within 10 min.
r filtering the solution using a filter paper, fill up to 1000 mL with ddH2O.The solution can be stored at 4C for at least 3 months.
50- or 100-mL aliquots can be stored at 30C for a long time.
Alternatives:4%paraformaldehydesolutionwithoutpicric acidcanbeusedas thefixative solution.
To avoid oxidation of the paraformaldehydewithout picric acid, we recommend the solution to be
used within a week (storing at 4C until use). The solution can be stored at30C for a long time.
CRITICAL: Preparation of the fixative solution should be performed under the fume hood.To avoid scattering of paraformaldehyde powder, we recommend to use a weighing dish
rather than a weighing paper for measuring the powder. Picric acid is not only toxic but
also explosive when dried. Do not keep the lid open especially under the fume hood.agar solution (for embedding a fixed brain)
gent Final concentration Amount
r 3% (w/v) 6 g
rose S 0.3% (w/v) 0.6 g
M PB N/A Fill up to 200 mL
al N/A 200 mL
solve agar and agarose S by boiling the solution using microwave radiation.
uot the solution into 50-mL conical tubes and keep until the liquid becomes solid.
id agar can be stored at 4C for at least 3 months.
rate-based antigen retrieval solution (pH 6.0)
gent Final concentration Amount
odium citrate 10 mM 2.94 g
2O N/A Fill up to 1,000 mL
al N/A 1,000 mL
ust pH to 6.0 by adding 1 M HCl (nearly 9 mL for the 1,000-mL solution).
solution can be stored at 20C–25C for 1 year.For antigen retrieval, boil the solution using microwave irradiation.
Soak sections in it and keep at 90C for 10–30 min in the laboratory incubator.STAR Protocols 2, 100743, September 17, 2021
ll
OPEN ACCESSProtocolAfter that, return it to 20C–25C and carry out performing immunohistochemistry.
Alternatives: As another option, the Tris-EDTA solution can be used for antigen retrieval. Add
1.21 g Tris base and 0.372 g EDTA in 1,000 mL ddH2O and adjust pH to 9.0 by adding 1 M
NaOH (nearly 0.3 mL). The solution can be stored at 20C–25C for 1 year.10% normal donkey serum with 0.3% Triton X-100
Reagent Final concentration Amount
Normal donkey serum 10% (v/v) 1 mL
20% Triton X-100 0.3% (w/v) 150 mL
0.1 M PB N/A 9 mL
Total N/A 10 mL
The solution can be stored at 4C for 1 month.
10% sucrose solution
Reagent Final concentration Amount
Sucrose 10% (w/v) 10 g
0.1 M PB N/A Fill up to 100 mL
Total N/A 100 mL
The solution can be stored at 4C for 1 month.
30% sucrose solution
Reagent Final concentration Amount
Sucrose 10% (w/v) 30 g
0.1 M PB N/A Fill up to 100 mL
Total N/A 100 mL
The solution can be stored at 4C for 1 month.
Antifreeze solution
Reagent Final concentration Amount
Glycerol 30% (w/v) 150 g
Ethylene glycol 30% (v/v) 150 mL
NaCl 0.85% (w/v) 4.25 g
0.4 M TB* 0.04 50 mL
ddH2O N/A Fill up to 500 mL
Total N/A 500 mL
The solution can be stored at 30C for a long time.
*For preparation of 0.4 M TB, dissolve 4.85 g Tris-HCl and 1.11 g Tris base in 100-mL ddH2O.
Gelatin solution for preparing gelatin-coated glass slides
Reagent Final concentration Amount
Gelatin 1% (w/v) 2 g
Chromium (III) Potassium Sulfate$12H2O 0.005% (w/v) 10 mg
ddH2O N/A 200 mL
Total N/A 200 mL
Add chromium (III) potassium sulfate after melting gelatin by heating the solution at 60C and filter the solution. We recom-
mend to prepare the solution on the day of use.
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Figure 1. Development of mouse model for the infraorbital nerve (ION) cut
(A) A setup for mouse surgery.
(B) Exposed ION. Scale bar, 5 mm.
(C) No running ION after ION cut (IONC). Scale bar, 5 mm.
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OPEN ACCESS ProtocolAfter washing glass microscope slides with 70% ethanol and then with ddH2O, dip them into the
warm gelatin solution keeping at 60C.
Dry gelatin-coated glass slides in the laboratory incubator at 40C for 12–16 h (at least for 4–6 h).STEP-BY-STEP METHOD DETAILS
Development of mouse model for the infraorbital nerve injury
Timing: 15–20 min
In the mouse whisker somatosensory pathway, thalamic neurons undergo synaptic remodeling not
only during development but also after peripheral nerve injury. To examine structural and functional
changes in synapses after peripheral nerve injury, we perform transection of the infraorbital nerve,
which is the second branch of the trigeminal nerve and conveys tactile information from the whiskers.
1. Mouse anesthesia
a. Anesthetize a mouse (older than 3 weeks) by 2–3% isoflurane in an anesthesia induction cham-
ber for 5 min (Figure 1A).
b. Anesthesia is maintained by intraperitoneal injection of a mixture of medetomidine (0.3 mg/
kg), midazolam (4 mg/kg), and butorphanol (5 mg/kg) in saline (0.9% NaCl).
Note: We use C57 BL/6 wild type mice or transgenic mice produced from C57 BL/6 genetic
background of both sexes for this study. Synaptic remodeling in the thalamus is observed
both in male and female mice. Mice in the age range of 3–8 weeks old, which corresponds
to the period after the developmental synapse remodeling and maturation in the whisker thal-
amus (Takeuchi et al., 2014), are used.
2. Unilateral digestion of the infraorbital nerve
a. Place a mouse on a heating pad (40C) (Figure 1A) and make a vertical incision between the
whisker pad and the eye (Figure 1B).
b. Expose the infraorbital nerve under a microscope using two forceps (Figure 1B). The nerve
should be freed from the connective tissue without bleeding. Troubleshooting 1
c. Locally anesthetize the nerve by applying 2% xylocaine with 1:80,000 adrenaline on the sur-
face of the nerve using a 1-mL syringe with a 26- or 27-gauge needle.
d. Lift the nerve up and cut the nerve at a central site first and then a peripheral site at a distance
of 1–2 mm from the central site to prevent axonal regeneration (Figure 1C).10 STAR Protocols 2, 100743, September 17, 2021
Figure 2. The timing and workflow of stereotaxic injection
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OPEN ACCESSProtocol3. Postoperative care
a. After suturing the skin, inject atipamezole (0.1 mg/kg) intraperitoneally to reverse the sedative
effect of medetomidine.
b. Return the mouse to the home cage and house until the electrophysiological or histological
experiment is performed.
Note: Synaptic remodeling in the thalamus is induced 5–6 days from the nerve cut (Takeuchi
et al., 2012).
CRITICAL: Operation should be terminated within 30 min because sedative effect ofmedetomidine usually continues only 30 min from the intraperitoneal injection. We
recommend continuous administration of 0.5–1% isoflurane (or sevoflurane) in addition
to medetomidine injection.Stereotaxic injection
Timing: 25–60 min
Refer to ‘‘materials and equipment’’ for information about reagents used. The timing and workflow
are depicted in Figure 2.
4. Mouse anesthesia
a. Anesthetize a mouse by 2–3% isoflurane in an anesthesia induction chamber for 5–10 min (Fig-
ure 1A).
b. Anesthesia is maintained by intraperitoneal injection of a mixture of medetomidine (0.3 mg/
kg), midazolam (4 mg/kg), and butorphanol (5 mg/kg) in saline (0.9% NaCl).
Note:When the operation is expected to be prolonged (more than 25 min), apply 0.5–1% iso-
flurane continuously to maintain anesthesia. Body temperature should be monitored and
maintained during the operation.STAR Protocols 2, 100743, September 17, 2021 11
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a. Place the anesthetized mouse in a stereotaxic apparatus using an auxiliary ear bar (Figure 2A).
Apply 2% xylocaine jelly to the outer ear for local anesthesia using a swab before the auxiliary
ear bar is attached.
b. Apply 0.3% ofloxacin gel to both eyes using a swab to protect eyes during the operation.
c. Make a skin incision to expose a skull after local anesthesia with 2% xylocaine jelly application.
d. Adjust the nose position using an incisor bar until z coordinates of bregma and lambda
become the same.
e. Drill the skull above the marked sited using a micromotor system with a steel bur. To reduce
heat damage of the brain, the drilling should be paused by cooling with saline of 20C–25C.
Troubleshooting 2
Note: Diameter of the drilled hole is typically around 0.5 mm.
6. Injection using a Hamilton syringe (Figure 2)
a. Attach a 10 mL Hamilton syringe with a stainless-steel needle to a syringe holder connected
with a microprocessor-controlled injector.
CRITICAL: We recommend the use of a 35-gauge beveled needle to reduce brain damage.After the injection, the Hamilton syringe with a needle should be washed 2–3 times with
water and then with 70% ethanol.b. Fill the injection solution into the needle from the tip.
c. Move the syringe to the surface of the drilled site.
d. Insert the needle into the target depth of the brain and inject the solution continuously.
e. Remove the needle.
Note: After the injection, we recommend the needle remained in place for at least 5 min
before being withdrawn. Volume of the injection solution typically ranges between 100 and
500 nL. Injection is completed within 5 min. The speed of the injection is adjusted to 40–
100 nL/min.
f. Fill the drilled hole with hemostatic gelatin sponge (e.g., Spongel, see ‘‘key resources table’’)
and close the scalp wound.
g. Inject atipamezole (0.1 mg/kg) intraperitoneally to reverse the sedative effect of medetomi-
dine.
h. Return the mouse to the home cage and house until the electrophysiological or histological
experiment is performed.
Note: Injection by air pressure can be performed using Picospritzer as described in the recent
protocol (Okamoto et al., 2020). When you need to inject into more restricted site or you need
to reduce neuronal damages, iontophoretic delivery is available as described below (step 7).
7. Iontophoretic delivery using a glass pipette (Figure 2)
a. Pull borosilicate glass capillaries (1 or 1.5 mm O.D.) using a single pull with a micropipette
puller (P1000 or P97, Sutter Instrument).
Note: We use a single cycle for pulling an injection pipette using the micropipette puller (P-
1000 or P-97, Sutter Instrument) to obtain pipettes with long tapers (e.g., step 1: heat,
ramp; pull, 50; velocity, 200; delay, 250; pressure, 500).
b. Cut off the tip of a pulled-pipette using scissors (tip diameter, 20–50 mm).12 STAR Protocols 2, 100743, September 17, 2021
Figure 3. Focal injection using iontophoresis
(A) A retrograde tracer, Alexa Fluor 647-conjugated cholera toxin subunit B (CTB647, 0.2% in ddH2O), is
iontophoretically delivered to the dorsal part of the thalamic ventral posteromedial nucleus (VPM). VPM is identified
by VGLUT2 immunohistochemistry using a guinea pig anti-VGluT2 antibody and an Alexa Fluor 488-conjugated
secondary antibody. Gray-scale images are acquired using an epifluorescence microscope (Axio Scope.A1, Carl Zeiss)
equipped with a cooled CCD camera (QSI RS 6.1, Quantum Scientific Imaging) and pseudocolored using Adobe
Photoshop software. D, dorsal; L, lateral; VPL, ventral posterolateral nucleus. Scale bar, 0.5 mm.
(B) Retrogradely labeled cells in the ventral part of the principal trigeminal nucleus of the brainstem (Pr5) in the
contralateral hemisphere. M, medial. Scale bar, 0.5 mm.
ll
OPEN ACCESSProtocolc. Draw the injection solution into the pipette tip by capillary action and backfill saline slowly us-
ing the 1-mL syringe with a flexible needle. Troubleshooting 3
d. Insert an Ag/AgCl wire into the pipette and attach the pipette to the pipette holder.
e. Move the pipette to the surface of the drilled site.
f. Insert the pipette into the target depth of the brain and apply current with 7-s on/off cycles for
20–30 min using an iontophoresis pump. Troubleshooting 4
CRITICAL: Current polarity (positive or negative) depends on the reagent and the solventused (e.g. ddH2O, saline, or 0.1 M PBS). Current intensity depends on the tip diameter or
the target region and usually ranges between 0.3–5 mA. To make focal injection, lower cur-
rent intensity is suitable for injection into the neocortex (Ueta et al., 2014), while larger one
is necessary for injection into dense structures such as the thalamus and brainstem (Ueta
and Miyata, 2021).g. Remove the pipette. Leaving the pipette before withdrawn is not necessary when the diameter
of the pipette is 20 mm, because the injection solution does not leak out from such narrow tip
(Figure 3).
h. Carry out postoperative care as described above.
Note: For local depletion of microglia, PLX3397, which inhibits microglial proliferation, or
clodronate liposomes, which induces microglial apoptosis, is available (Figure 4). For local
activation of microglia, lipopolysaccharides is available (refer to ‘‘key resources table’’)
(Ueta and Miyata, 2021). Genetic regulation of local microglia by such as the diphtheria toxin
receptor expression system using transgenic mouse lines (Willis and Vukovic, 2020), or virally-
introduced DREADD system are also useful (Grace et al., 2018). These transgenic mouse lines
or DREADD expressing viral vectors under microglial promoter are commercially available
from the Jackson Laboratory or Addgene.
Focal injection using iontophoresis is also useful for neuronal tracing from a restricted area (Ueta et al.,
2014). For example, we can successfully obtain retrogradely labeled cells in the whisker region in the
brainstem, which corresponds to the ventral part of the principal trigeminal nucleus (Pr5), by a small in-
jection (100–200mmof the diameter) restricted in thewhisker thalamus, which corresponds to thedorsal
part of the ventral posteromedial nucleus (VPM) (Figure 3). In this protocol, Alexa Fluor 647-conjugated
cholera toxin subunit B is usedas a retrograde tracer (0.2%,dissolved in 0.1or 0.05MPBS) (Figure 3).WeSTAR Protocols 2, 100743, September 17, 2021 13
Figure 4. Local and brain-wide depletion of microglia
(A) Clodronate liposomes, which induce apoptosis of microglia, are locally injected to the brainstem using a Hamilton
syringe. No immunoreactivity against a myeloid cell marker Iba1 is found in the injection site. Immunohistochemistry is
performed using a rabbit anti-Iba1 antibody and an Alexa Fluor 488-conjugated secondary antibody. Gray-scale
images are acquired using the epifluorescence microscope same as in Figure 3 and inverted using Adobe Photoshop
software. Scale bar, 0.5 mm (left) or 0.2 mm (right).
(B) Brain-wide microglia are depleted by systemic administration of PLX3397, which inhibits microglial proliferation.
An arrow indicates a remaining Iba1-positive cell in the brainstem. Scale bar, 0.2 mm.
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OPEN ACCESS Protocolhave previously utilized Alexa Fluor 555-conjugated cholera toxin subunit B (0.2%) and obtained suc-
cessful retrograde labeling from the restricted cortical layers (Ueta et al., 2014).
Whole-cell patch-clamp recording using acute brain slices
Timing: R2 h
The timing and workflow are depicted in Figure 5.
8. Preparation of solutions (refer to ‘‘materials and equipment’’)
a. 103 aCSF stock solution
b. 1M CaCl2 solution
c. 1M MgCl2 solution
d. Cutting solution
e. Intracellular pipette solution for voltage-clamp or current-clamp recording
9. Preparation of acute brain slices
a. Dilute the 103 aCSF stock solution to 1 L with ddH2O, add 3.6 g glucose (20 mM), and bubble
with a mixture of 95% O2 and 5% CO2.
b. Add 2 mL of 1M CaCl2 solution (2 mM) and 1 mL of 1M MgCl2 solution (1 mM).
c. Transfer 100–150 mL of aCSF to a glass beaker and place it in the water bath adjusted to 32C.
Bubble this aCSF solution continuously.
d. Bubble the cutting solution on ice.14Note: To improve recovery of neurons, add Na-ascorbate (5 mM), Na-pyruvate (3 mM), and
thiourea (2mM) to both aCSF and the cutting solution. All of Na-ascorbate, Na-pyruvate, and
thiourea should be removed from aCSF during recording. Alternatively, add lactic acid
(4 mM) instead of Na-ascorbate, Na-pyruvate, and thiourea (Ueta et al., 2019). Lactic acid
is also removed from aCSF during recording.STAR Protocols 2, 100743, September 17, 2021
Figure 5. The timing and workflow of preparation of acute brain slices
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OPEN ACCESSProtocole. After a deep anesthesia of a mouse with isoflurane, perfuse 5 mL of the cooled cutting solution
transcardially using a 10 mL syringe with a 21-gause syringe needle within 1 min.
Note: More details about transcardial perfusion are described in the step 13.
f. Decapitate, remove the brain, and soak it into the cutting solution on ice for 1–3 min.
CRITICAL: Removing the brain and soaking it in the air-bubbled cutting solution afterdecapitation should be done quickly to avoid neuronal damages or death.g. Trim the brain on a filter paper using a razor blade or a surgical blade.
h. Glue the brain block onto the electrical-taped specimen disk using cyanoacrylate (Aron alpha).
Glue a block of gelatin (2–3%) behind the brain block. Place the disk onto the buffer tray with
the cutting solution continuously bubbled with 95% O2 and 5% CO2.
i. Cut sagittal slices of 250- or 300-mm thickness including the whisker thalamus (VPM) using a
vibratome with a razor blade and collect on the holding chamber in the water bath. Cutting
speed is basically 0.04 mm/s (VT1200S, Leica Microsystems). Frequency amplitude normally
ranges between 0.4 and 0.5 mm (VT1200S). Troubleshooting 5
Note: A double edge razor blade is cut in half using tinner’s snips and is attached to blade
holder of the vibratome. We can cool the buffer tray with ice or icepacks and apply the
sherbet-like chilled cutting solution in the buffer tray. Temperature during slice cutting
may affect various physiological properties probably depending on the cell type or the
age of animals (e.g., Eguchi et al., 2020). It is important to select appropriate methods de-
pending on the application or the purpose of experiments.
j. After cutting, incubate brain slices in the aCSF solution for 30 min at 32C using a water bath
and then for at least 30 min at 20C–25C until use.STAR Protocols 2, 100743, September 17, 2021 15
Figure 6. A setup for whole-cell patch clamp recording and example experiments
(A) A setup for patch-clamp experiments.





ProtocolNote: Electrophysiological recording is normally finished within 6–8 h from the slice cutting.
To obtain synaptic responses, we recommend to finish recordings within 4–6 h from the
decapitation.10. Assessment of number of innervated axons by recording of excitatory postsynaptic currents
(EPSCs) in individual neurons of the whisker thalamus (Figure 6)a. To block inhibitory postsynaptic currents, add GABAA receptor antagonist bicuculline me-
thochloride (10 mM) and GABAB receptor antagonist CGP55845 hydrochloride (1 mM) to
the perfusing aCSF continuously bubbled with 95% O2 and 5% CO2. Temperature of aCSF
is maintained at 31C–32C using a line heater (Figure 6A).
b. Establish a whole-cell patch on a thalamic neuron which is identified using a near-infrared
camera (C3077-79, Hamamatsu Photonics)-equipped microscope (BX51WI, Olympus
Corp.) with a 603 water-immersion objective (numerical aperture = 0.9, Olympus Corp.).
Note: VPM is visually identifiable in the bright-field images (Takeuchi et al., 2012; 2014). VPM in
miceconsists ofglutamatergic thalamocortical neuronsand ismostlydevoidof local interneurons.
c. EPSC is evoked by an electrical stimulation using a concentric electrode placed on the
lemniscal fiber bundle.
d. The number of EPSC steps corresponds to the number of axons innervating a recorded
neuron. For example, a single neuron which receives three axonal inputs expresses three
EPSC steps when a stimulus intensity is gradually increased, but a neuron receiving a single
axonal input expresses a single EPSC step in an all-or-none fashion (Figure 6B).
Note: We use 5 or 6 cycles for pulling a whole-cell patch pipette (4–8 MU) using the micropi-
pette puller to obtain pipettes with short tapers (e.g., step 1: heat, ramp; pull, 0; velocity, 19,
delay, 1; pressure, 500; step 2: ramp – 5; pull, 0; velocity, 19; delay, 1; steps 3 and 4: heat,
ramp – 15; pull, 0; velocity, 19; delay, 1; steps 5 and 6: ramp – 25; pull, 0; velocity, 20; delay,
1). We usually increase or decrease velocity in the last step to correct the tip diameter. The
internal solution is kept on ice during recording. A recent detailed protocol for patch-clamp
techniques would help your experiments (Manz et al., 2021).
CRITICAL: Neurons in the mouse whisker thalamus receive glutamatergic excitatory in-puts from lemniscal fibers, which originate from the brainstem, and/or from corticothala-
mic axons. EPSCs evoked by these two different pathways have different EPSC kinetics
and short-term plasticity: lemniscal fiber-evoked EPSCs, fast EPSC decay and paired-pulseSTAR Protocols 2, 100743, September 17, 2021
Figure 7. Post hoc visualization of cell morphology after electrophysiological recording
A VPM neuron is visualized with Alexa Fluor 488-conjugated streptavidin. Immunohistochemistry against vesicular
glutamate transporter type 2 (VGluT2) and Alexa Fluor 647-conjugated secondary antibody is simultaneously
performed. Gray-scale images are acquired using a fluorescent microscope (BZ-X810, Keyence) and pseudocolored.
The slice is resectioned at 40 mm. Scale bar, 20 mm.
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OPEN ACCESSProtocoldepression; corticothalamic EPSCs, slower decay of EPSCs and paired-pulse facilitation
(Miyata and Imoto, 2006).11. Post hoc visualization of dendritic and axonal morphologies of a recorded neuron.a. After recording, the slices of 250- or 300-mm thickness are collected in a glass vial or a 24-well
plate, soaked into the fixative solution, and stored for 12–16 h at 4C. The fixative solution of
2 mL is enough for a single slice.
Note: The slices can be stored in the fixative solution at 4C for few weeks. It can be possible to
store for longer time (e.g., 2–3 months).
b. Wash the slices three times with 0.1 M PBS for 10–20 min on a shaker.
c. Incubate the slices with fluorescent streptavidin (e.g., Alexa Fluor 488-conjugated streptavi-
din, 1:500) in 0.1 M PBS with 0.05% Triton X-100 for 2–3 h at 20C–25C or 12–16 h at 4C.
d. Wash the slices two times with 0.1 M PBS for 5–10 min and then with 0.1 M PB for 5–10 min to
remove NaCl.
e. Mount the slices on a gelatin-coated glass slide (refer to ‘‘materials and equipment’’).
Note: Use spacers (two sheets of electrical tape, 200 mm thickness for one sheet) when sec-
tions are coverslipped not to flatten the slices.
f. Seal the sections with antifade mountant and apply a coverslip.
Note:After fixation, the sections can be resectioned at a thickness of 40 or 50 mm. Such thinner
sections are useful for simultaneous immunohistochemical staining (Nagumo et al., 2020)
(Figure 7).
Immunohistochemistry of fixed brain tissue
Timing: 2–3 days
To identify whisker-originated axon terminals in the whisker thalamus, we have crossed a Krox20-Cre
mouse and an Ai34D reporter mouse, which expresses synaptophysin-tdTomato under Cre inducing
conditions (Figure 8). In the brainstem trigeminal nucleus of Krox20-Cre mice, Cre is expressed inSTAR Protocols 2, 100743, September 17, 2021 17
Figure 8. Schematic illustrating the identification of pathway-specific axon terminals in the thalamus and example sections
(A) Identification of whisker-origin and ectopic (non-whisker-origin) axon terminals in the thalamic VPM using Krox20-Cre mice crossed with Ai34D mice,
which express synaptophysin-tdTomato under Cre.
(B) Cre recombinase is expressed in principal neurons in the ventral whisker region of Pr5. Scale bar, 0.5 mm.
(C) Axon terminals in VPM. Gray-scale images are acquired using a confocal laser scanning microscope (LSM710, Carl Zeiss) and pseudocolored. Scale
bar, 40 mm.
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OPEN ACCESS Protocolthalamus-projecting principal neurons in the whisker region but not in neurons in non-whisker re-
gions (Bechara et al., 2015; Takeuchi et al., 2014; Voiculescu et al., 2000).
The timing and workflow are depicted in Figure 9.
12. Preparation of solutions (refer to ‘‘materials and equipment’’)18a. 0.1 M PB and PBS
b. 0.05 M Tris buffer (TB) and Tris-buffered saline (TBS)
c. Prefixative solution
d. Paraformaldehyde-based fixative solution
e. Agar solution for embedding a brain block
f. Antigen retrieval solutions
g. 10% normal donkey serum solution with 0.3% Triton X-100
h. 10% or 30% Sucrose solution
i. Antifreeze solution13. Preparation of fixed brain tissuea. Deeply anesthetize the Krox20-Cre : Ai34Dmouse with isoflurane and place it on the shallow
tray.
b. Make an abdominal incision on the liver and find the xiphoid process.STAR Protocols 2, 100743, September 17, 2021
Figure 9. The timing and workflow of immunohistochemistry using fixed brain sections
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OPEN ACCESSProtocolc. Lift up the xiphoid process, expose the pleural cavity by making a lateral incision in the dia-
phragm, and cut along the lateral wall of the rib cage on both sides until both the heart and
the thymus, which is in front of and above the heart, are exposed.
Note: To avoid injuring the lung, carefully displace it during cutting the rib cage.
d. Make a small incision in the right atrial ear and quickly insert a 21-gauge needle, which con-
nects to the peristaltic pump system (Figure 9), to the left ventricle of the heart.
Note: You can insert the needle to the left ventricle first and cut the right atrial ear next.
e. Perfuse the fixative solution followed by the 5 mL of the prefixative solution at 20C–25C for
10–15 min using a peristaltic pump. Troubleshooting 6
Note: The volume of the fixative solution is twice the body weight.STAR Protocols 2, 100743, September 17, 2021 19
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OPEN ACCESS Protocolf. Brains are usually post-fixed in the fresh fixative for 30 min or 12–16 h at 4C. After post-fix-
ation, the fixative solution is replaced by 0.1 M PB.
Pause point: Although the fixed brain can be stored in 0.1 M PB for few weeks at 4C, we
recommend to prepare thin sections within few days from the perfusion.
14. Preparation of thin sections using a vibratomea. Trim the fixed brain on the brain slicer matrix using a microtome blade.
b. Glue the brain block onto the specimen disk using Aron Alpha. Mount the block with agarose
gel solution using amold (20mL cut syringe). Allow the disk to cool to set the gel in the refrig-
erator.
c. Remove the mounted brain block from the disk after trimming gels and glue onto the spec-
imen disk again.
Note: By this step, the brain block embedded in agarose gel is tightly glued onto the disk.
d. Set the disk onto the buffer tray with cooled 0.1 M PB.
e. Cool the buffer tray with ice or ice packs during cutting using a vibratome with an injector
blade. Cutting speed ranges between 0.05–0.2 mm/s (scale 1–4.5 for Leica VT1000S). Fre-
quency is normally set at 40–50 Hz (scale 4–5).
f. Collect sections and submerge them into a 24-well plate with 0.1 M PB.
Note: To observe both the brainstem and the thalamus, we usually use coronal sections for
histological experiments. Section thickness is usually set to 40 or 50 mm for handling and anti-
body penetration. We use sections of 8–20 mm thickness for analyzing colocalization of
different markers or labeling in individual cell somata using single-focus images under epi-
fluorescence microscopy.
Pause point: Sections may be stored at 4C for a couple of weeks, but we recommend that
sections are immersed in an antifreeze solution after a sucrose-substitution procedure and
kept at 30C for long-term storage. Use a cryostat to obtain thinner sections after a su-
crose-substitution procedure (10% sucrose for 4–6 hours to 12–16 h and 30% sucrose for
one day or few days at 4C).
15. Fluorescent immunohistochemistry on free-floating sections20a. Wash the sections three times with 0.1 M PBS for 5–10 min in a 12-well plate on a shaker.
b. Incubate the sections with primary antibody (guinea pig polyclonal antibody against
vesicular glutamate transporter type2 (VGluT2), 1:500 or 1,000) in 10% normal donkey
serum solution with 0.3% Triton X-100 for 12–16 h at 4C or 2–3 h at 20C–25C on an orbital
shaker.
Note: Use 0.4–0.5 mL of the antibody solutions for a single well in a 12-well plate (less than 6
sections per well). Incubation with primary antibodies is usually carried out for 12–16 h at 4C.
Alternatives: For VGluT2 immunohistochemistry, rabbit polyclonal antibody is also available
and working well (refer to ‘‘key resources table’’).
c. Wash the sections three times with 0.1 M PBS for 5–10 min.
d. Incubate the sections with secondary antibody (Alexa Fluor 488-conjugated antibody against
guinea pig IgG, 1:500) and Fluorescent Nissl (NeuroTrace 435/455, 1:100) in 10% normal
donkey serum solution with 0.3% Triton X-100 for 12–16 h at 4C or 2–3 h at 20C–25C
on an orbital shaker.STAR Protocols 2, 100743, September 17, 2021
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OPEN ACCESSProtocolNote: Incubation with secondary antibodies is usually carried out in a dark place for 2–3 h at
20C–25C.
Alternatives: NeuN immunohistochemistry is also useful for visualizing neurons (refer to ‘‘key
resources table’’).
e. Wash the sections two times with 0.1M PBS for 5–10min and then with 0.1M PB for 5–10min.
f. Mount the sections on a gelatin-coated glass slide.
g. Seal the sections with antifade mountant and apply a coverslip. Troubleshooting 7
h. Acquire images using an epifluorescent microscope or by confocal microscopy. Trouble-
shooting 8
Note: Use spacers (Vinyl repair patch, 70 mm thickness) when sections are coverslipped for
confocal microscopic observation.
When we need to visualize myeloid cells including microglia, we use anti-Iba1 antibody for immuno-
histochemistry (refer to ‘‘key resources table’’) (Figure 4). Because anti-Iba1 antibody detects diverse
type of myeloid cells, we recommend to use anti-TMEM119 antibody for detecting microglia specif-
ically (refer to ‘‘key resources table’’) (Ueta and Miyata, 2021).
Alternatives:When we only need to acquire lower magnification images (e.g., 23, 43, or 53),
we use an aqueous mountant without antifade reagents (e.g., Fluoromount-G).EXPECTED OUTCOMES
Infraorbital nerve cut (IONC) induces microglial accumulation in the whisker region of the brainstem
but not in the thalamus (Ueta and Miyata, 2021). Using stereotaxic injections, we can manipulate
local microglial activity as well as neuronal activity (for genetic approaches, refer Willis and Vukovic,
2020). Systemic microglial depletion using oral administration of microglial inhibitor is also commer-
cially available and successful (Elmore et al., 2014; Ueta and Miyata, 2021). Combined these local
and systemic regulation of microglia, the understanding of the role of microglia in various develop-
mental and pathophysiological conditions will be progressed.
To understand the mechanisms for synaptic remodeling, it is important to know both structural and
physiological characteristics of synapses. A whole-cell patch-clamp recording from an identified sin-
gle neuron in acute brain slices has some limitations described below, but is still useful for detailed
analyses of synaptic properties including kinetics and structure; for example, we can estimate the
number of innervated axons by counting EPSC steps. In addition, dendritic and axonal morphol-
ogies can be reconstructed by biocytin or neurobiotin filling during recording and post hoc visual-
ization (Ueta et al., 2019; Ueta and Miyata, 2021). Combined electrophysiological and anatomical
techniques, together with utilization of region-specific Cre mice, are advantageous strategy to label
and manipulate specific circuits or projection pathways.LIMITATIONS
Depletion or activation effect of microglia by using a single focal injection will not continue for a
long-time period. We have observed that microglia are still depleted at the injection site after 5–
6 days from a single injection of clodronate liposomes (Ueta and Miyata, 2021). Genetic approaches
using microglia-targeted recombinant viral infection probably overcome this limitation. In addition,
genetic approaches enable targeting different microglial population with activation of state-specific
gene expression (Friedman et al., 2018; Hammond et al., 2019). Repopulation of microglia is another
important issue when microglia are systemically or locally depleted, because repopulated microglia
have both neurotoxic and neuroprotective effects (Rubino et al., 2018; Willis et al., 2020), and alsoSTAR Protocols 2, 100743, September 17, 2021 21
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OPEN ACCESS Protocolbecause the rate of microglial repopulation depends on the extent of depletion (Najafi et al., 2018).
Long-term effects of microglial manipulation will be highlighted in future studies.
It is difficult to know whether individual axonal input originates from the whisker region or non-
whisker regions in electrophysiological recording. However, using Cre-off viral injection into
Krox20-Cre mice combined with direct recording from an identified presynaptic terminal, we have
recently enabled the pathway-specific measurement of electrophysiological properties in acute sli-
ces (Midorikawa and Miyata, 2021).TROUBLESHOOTING
Problem 1
Bleeding occurs intraoperatively (step 2).Potential solution
Add one drop of saline or 2% xylocaine with 1:80,000 adrenaline using a 1-mL syringe with a 26- or
27-gauge needle to stop bleeding.Problem 2
Bleeding occurs during drilling (step 5).Potential solution
Place an absorbent cotton piece wet with warmed saline for a few minutes to stop bleeding. Rapid
vibrations of the hand motor will cause bleeding from the skull. To minimize such vibrations, the
hand motor can be controlled by a micromanipulator with a drill holder (e.g., Cat#SD-102,
Narishige).Problem 3
No capillary action (step 7).Potential solution
The tip diameter is too narrow (probably smaller than 20 mm). Cut off the tip using scissors or gently
break the tip using forceps.Problem 4
No current flows (step 7).Potential solution
It is probably due to an air bubble in the pipette. Tap the pipette gently not to mix the injection so-
lution and backfilled saline to avoid reducing concentration of the injection solution. In our experi-
ments, injection solution is filled within the tapering part of the glass capillary. Normally, an Ag/AgCl
wire is incapable of inserting into the thin tapering part. So, backfilled saline is needed as the electric
carrier. Alternatively, the injection solution can be backfilled. In that case, collect the solution after
finishing the injection and use it in the next experiments.Problem 5
Vibratome fails to accurately and repeatedly slice sections (step 9).Potential solution
The brain block is not tightly glued onto specimen disk. We recommend to cut at low cutting speed
(around 0.05 mm/s) after the brain block is tightly glued on the disk again. If that doesn’t work, pre-
pare thicker sections (e.g., 100 mm).22 STAR Protocols 2, 100743, September 17, 2021
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Uneven whole-brain fixation due to insufficient perfusion (step 13).
Potential solution
When the solution is released from the nose and/or the mouth during perfusion, it does not flow to
the brain. This is probably due to clogged or ruptured blood vessels. To avoid this, remove air bub-
bles from a silicone tube connecting to a needle before inserting it into the left ventricle. We recom-
mend to use a blunt-end needle, which can be made from a syringe needle by using diagonal and
needle-nose pliers for example.
Problem 7
Undesirable air bubbles are formed under the coverslip (step 15).
Potential solution
After drying sections, place a generous amount (0.2–0.3 mL mountant for one slide) of mountant on
the one side of the glass slide. The use of insufficiently small amount of mountant will result in air
bubble formation. Hold one edge of a coverslip with fine tweezers (curved one is better) and place
the other edge of the coverslip on the droplet. Slowly lower the tweezers together with the coverslip
until the tip of the tweezers is close to the surface of the glass slide. Then, slowly pull out the tweezers
from under the coverslip. Absorb excess mountant using a twisted paper (e.g., KimWipes). Finally,
seal the coverslip with nail polish.
Problem 8
The signal is weak or the background of an acquired image is high (step 15).
Potential solution
There may be several causes. We recommend to perform antigen retrieval before antibody penetra-
tion or use TBS as a buffer instead of PBS (refer to ‘‘materials and equipment’’), because PBS is known
to inhibit some enzymatic actions. Tyramine-based signal enhancement method will be helpful as
described in a recent protocol (Okamoto et al., 2020).
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Yoshifumi Ueta (yueta@twmu.ac.jp).
Materials availability
This study did not generate new unique reagents.
Data and code availability
This study did not generate any unique data sets or code.
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